Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -76.84% | 26.47% | 6.56% | -30.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -76.84% | 26.47% | 6.56% | -30.40% |
| Cost of Revenue | -11.49% | -20.84% | -23.39% | -27.75% | -22.26% |
| Gross Profit | 11.45% | 20.81% | 23.40% | 27.76% | 22.25% |
| SG&A Expenses | -10.17% | -9.02% | -11.32% | -12.53% | -10.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.17% | -18.15% | -20.71% | -24.47% | -19.67% |
| Operating Income | 11.14% | 18.13% | 20.71% | 24.48% | 19.66% |
| Income Before Tax | 13.83% | 21.43% | 17.64% | 23.44% | 18.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.68% | 21.29% | 17.64% | 23.44% | 18.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.68% | 21.29% | 17.64% | 23.44% | 18.93% |
| EBIT | 11.14% | 18.13% | 20.71% | 24.48% | 19.66% |
| EBITDA | 11.33% | 18.80% | 21.62% | 25.53% | 20.52% |
| EPS Basic | 31.96% | 36.80% | 32.60% | 35.98% | 27.91% |
| Normalized Basic EPS | 32.38% | 37.45% | 39.92% | 41.79% | 32.71% |
| EPS Diluted | 31.96% | 36.80% | 32.60% | 35.98% | 27.91% |
| Normalized Diluted EPS | 32.38% | 37.45% | 39.92% | 41.79% | 32.71% |
| Average Basic Shares Outstanding | 26.57% | 24.16% | 22.14% | 20.02% | 13.23% |
| Average Diluted Shares Outstanding | 26.57% | 24.16% | 22.14% | 20.02% | 13.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |